Old malaria and HIV drugs repurposed to fight ovarian cancer
NCT ID NCT06971744
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining two drugs that affect cell cleanup (hydroxychloroquine and nelfinavir) with standard maintenance therapy (bevacizumab) can help keep ovarian cancer from growing back. About 38 women with recurrent high-grade serous ovarian cancer will take these pills plus an IV infusion every three weeks. The study will check safety and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hydroxychloroquine, nelfinavir, and bevacizumab
What this could lead to
If it works, this could offer a new maintenance option to delay cancer progression in patients with recurrent ovarian cancer.
What could go wrong
This is a small, early-phase trial (38 participants) with no control group, so results may not be conclusive. The drugs can cause side effects like nausea or vision changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact